Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview

被引:177
作者
Kciuk, Mateusz [1 ,2 ]
Marciniak, Beata [2 ]
Kontek, Renata [2 ]
机构
[1] Univ Lodz, Doctoral Sch Exact & Nat Sci, PL-90237 Lodz, Poland
[2] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Biotechnol & Genet, PL-90237 Lodz, Poland
关键词
irinotecan; SN-38; topoisomerases; drug combinations; new formulations; drug resistance; METASTATIC COLORECTAL-CANCER; CELL LUNG-CANCER; TOPOISOMERASE-I INHIBITORS; PHASE-III TRIAL; ACTIVE METABOLITE; DNA TOPOISOMERASE; HEPATOCELLULAR-CARCINOMA; COMBINATION CHEMOTHERAPY; LIPOSOMAL IRINOTECAN; ANTITUMOR-ACTIVITY;
D O I
10.3390/ijms21144919
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Irinotecan has been used in the treatment of various malignancies for many years. Still, the knowledge regarding this drug is expanding. The pharmacogenetics of the drug is the crucial component of response to irinotecan. Furthermore, new formulations of the drug are introduced in order to better deliver the drug and avoid potentially life-threatening side effects. Here, we give a comprehensive overview on irinotecan's molecular mode of action, metabolism, pharmacogenetics, and toxicity. Moreover, this article features clinically used combinations of the drug with other anticancer agents and introduces novel formulations of drugs (e.g., liposomal formulations, dendrimers, and nanoparticles). It also outlines crucial mechanisms of tumor cells' resistance to the active metabolite, ethyl-10-hydroxy-camptothecin (SN-38). We are sure that the article will constitute an important source of information for both new researchers in the field of irinotecan chemotherapy and professionals or clinicians who are interested in the topic.
引用
收藏
页码:1 / 21
页数:21
相关论文
共 129 条
[1]   Type IA topoisomerases can be "magicians" for both DNA and RNA in all domains of life [J].
Ahmad, Muzammil ;
Xu, Dongyi ;
Wang, Weidong .
RNA BIOLOGY, 2017, 14 (07) :854-864
[2]   Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine [J].
Ahmed, Shabbir ;
Zhou, Zhan ;
Zhou, Jie ;
Chen, Shu-Qing .
GENOMICS PROTEOMICS & BIOINFORMATICS, 2016, 14 (05) :298-313
[3]   A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer [J].
Alamgeer, Muhammad ;
Watkins, D. Neil ;
Banakh, Ilia ;
Kumar, Beena ;
Gough, Daniel J. ;
Markman, Ben ;
Ganju, Vinod .
INVESTIGATIONAL NEW DRUGS, 2018, 36 (02) :288-298
[4]   CD133-targeted delivery of self-assembled PEGylated carboxymethylcellulose-SN38 nanoparticles to colorectal cancer [J].
Alibolandi, Mona ;
Abnous, Khalil ;
Anvari, Sajjad ;
Mohammadi, Marzieh ;
Ramezani, Mohammad ;
Taghdisi, Seyed Mohammad .
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2018, 46 :S1159-S1169
[5]   FOLFIRI plus bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9-FFCD 0802) [J].
Aparicio, Thomas ;
Linot, Benjamin ;
Le Malicot, Karine ;
Bouche, Olivier ;
Boige, Valerie ;
Francois, Eric ;
Ghiringhelli, Francois ;
Legoux, Jean-Louis ;
Ben Abdelghani, Meher ;
Phelip, Jean-Marc ;
Faroux, Roger ;
Dahan, Laetitia ;
Taieb, Julien ;
Bedenne, Laurent .
DIGESTIVE AND LIVER DISEASE, 2015, 47 (04) :271-272
[6]   Structural studies of type I topoisomerases [J].
Baker, Nicole M. ;
Rajan, Rakhi ;
Mondragon, Alfonso .
NUCLEIC ACIDS RESEARCH, 2009, 37 (03) :693-701
[7]   Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients [J].
Bao, Xun ;
Wu, Jianmei ;
Kim, Seongho ;
LoRusso, Patricia ;
Li, Jing .
JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (01) :20-34
[8]   A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer [J].
Bennouna, Jaafar ;
Deslandres, Marion ;
Senellart, Helene ;
de Labareyre, Cecile ;
Ruiz-Soto, Rodrigo ;
Wixon, Claire ;
Botbyl, Jeff ;
Suttle, A. Benjamin ;
Delord, Jean-Pierre .
INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) :138-147
[9]   Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis [J].
Bernards, Nicholas ;
Ventura, Manuela ;
Fricke, Inga B. ;
Hendriks, Bart S. ;
Fitzgerald, Jonathan ;
Lee, Helen ;
Zheng, Jinzi .
MOLECULAR PHARMACEUTICS, 2018, 15 (09) :4132-4138
[10]   A New-Class Antibacterial-Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV [J].
Bisacchi, Gregory S. ;
Manchester, John I. .
ACS INFECTIOUS DISEASES, 2015, 1 (01) :4-41